Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
17.7
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2024年7月1日〜2025年3月31日ConsolidatedJapanese GAAPNet Sales3,462¥ millionYear on year +17.7%Progress 75.0%
Operating profit-83¥ million
Ordinary income-97¥ million
Net income attributable to owners of the parent-186¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share-¥6.75
Financial position at period-end
Total assets5,710¥ million
of which net assets 3,826 ¥ millionEquity ratio 67.0%vs. prior year-end +2.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥4,619 million (YoY +16.1%)
Operating profit¥-107 million
Ordinary income¥-133 million
Net income¥-245 million
Revision to Earnings ForecastNot disclosed → Net Sales 4,619 / Operating profit -107 / Ordinary income -133 / Net income -245
Annual Dividend Forecast¥0 → Undecided
Factors Behind Changes in Business Performance
臨床診断装置が堅調に推移し、装置の売上増加に伴いメンテナンス関連製品の売上が増加した。海外連結子会社及び合弁会社の解散等の事業再編と費用抑制施策により販売費及び一般管理費が減少した。一方、連結子会社のソフトウェア不正使用に関連する対応費用として54百万円の特別損失を計上した。
Disclosure regarding the going concern assumption
重要事象等の記載あり。2期連続の損失や財務制限条項への抵触、当第3四半期累計の営業・経常・最終損失により重要な疑義を生じさせる事象又は状況が存在するが、重要な不確実性は認められないと判断している。なお、継続企業の前提に関する注記は該当事項なし。
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name ユニバーサル・バイオ・リサーチ株式会社
Impairment lossNone recorded for the period (shown as —)
Breakdown of extraordinary income (loss)Extraordinary income Gain on Sale of Fixed Assets ¥0 thousand, Gain on sale of shares in an affiliated company ¥8,987 thousand, Other ¥441 thousand, Total extraordinary income ¥9,429 thousand / Extraordinary loss Loss on sale of fixed assets ¥1,028 thousand, Impairment Losses ¥0 thousand, Loss on disposal of property, plant and equipment ¥3,467 thousand, Loss on reduction of fixed assets ¥0 thousand, Business-structure improvement costs ¥35,713 thousand, Compensation for damages ¥54,012 thousand, Other ¥0 thousand, Total extraordinary loss ¥94,223 thousand
Depreciation and amortization¥174,792 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End27,666,900
Treasury Shares at Period-End476,128
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年7月1日〜2025年3月31日 |
| Net Sales | ¥3,462 million (YoY +17.7%) |
| Operating profit | ¥-83 million |
| Ordinary income | ¥-97 million |
| Profit attributable to owners of the parent | ¥-186 million |
| Net income per share | -¥6.75 |
| Equity ratio | End of the current fiscal period 67 / End of previous period 64.8 |
| Total assets | ¥5,710 million |
| Net assets | ¥3,826 million |
| Full-year earnings forecast | Net Sales ¥4,619 million (YoY +16.1%) / Operating profit ¥-107 million / Ordinary income ¥-133 million / Net income ¥-245 million |
| Revision to Earnings Forecast | Not disclosed → Net Sales 4,619 / Operating profit -107 / Ordinary income -133 / Net income -245 |
| Annual Dividend Forecast | ¥0 → Undecided |
| Depreciation and amortization | ¥174,792 thousand |
| Impairment loss | None recorded for the period (shown as —) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on Sale of Fixed Assets ¥0 thousand, Gain on sale of shares in an affiliated company ¥8,987 thousand, Other ¥441 thousand, Total extraordinary income ¥9,429 thousand / Extraordinary loss Loss on sale of fixed assets ¥1,028 thousand, Impairment Losses ¥0 thousand, Loss on disposal of property, plant and equipment ¥3,467 thousand, Loss on reduction of fixed assets ¥0 thousand, Business-structure improvement costs ¥35,713 thousand, Compensation for damages ¥54,012 thousand, Other ¥0 thousand, Total extraordinary loss ¥94,223 thousand |
| Disclosure regarding the going concern assumption | 重要事象等の記載あり。2期連続の損失や財務制限条項への抵触、当第3四半期累計の営業・経常・最終損失により重要な疑義を生じさせる事象又は状況が存在するが、重要な不確実性は認められないと判断している。なお、継続企業の前提に関する注記は該当事項なし。 |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name ユニバーサル・バイオ・リサーチ株式会社 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 27,666,900 |
| Treasury Shares at Period-End | 476,128 |
| Factors Behind Changes in Business Performance | 臨床診断装置が堅調に推移し、装置の売上増加に伴いメンテナンス関連製品の売上が増加した。海外連結子会社及び合弁会社の解散等の事業再編と費用抑制施策により販売費及び一般管理費が減少した。一方、連結子会社のソフトウェア不正使用に関連する対応費用として54百万円の特別損失を計上した。 |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.臨床診断装置が堅調に推移し、装置の売上増加に伴ってメンテナンス関連製品の売上が増加した。加えて、海外連結子会社・合弁会社の解散などの事業再編と費用抑制施策により、販売費及び一般管理費が減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.